Head-To-Head Survey: Oruka Therapeutics (NASDAQ:ORKA) vs. FluoroPharma Medical (OTCMKTS:FPMI)

Oruka Therapeutics (NASDAQ:ORKA) and FluoroPharma Medical (OTCMKTS:FPMI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Oruka Therapeutics and FluoroPharma Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.00)	-4.00
FluoroPharma Medical	N/A	N/A	N/A	N/A	N/A

Insider & Institutional Ownership

56.4% of Oruka Therapeutics shares are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by insiders. Comparatively, 36.9% of FluoroPharma Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Oruka Therapeutics and FluoroPharma Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
FluoroPharma Medical	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Oruka Therapeutics and FluoroPharma Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
FluoroPharma Medical	0	0	0	0	0.00

Oruka Therapeutics presently has a consensus target price of $43.17, suggesting a potential upside of 79.86%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Oruka Therapeutics is more favorable than FluoroPharma Medical.

Summary

Oruka Therapeutics beats FluoroPharma Medical on 5 of the 8 factors compared between the two stocks.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

About FluoroPharma Medical

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.